Of the 86 managers this site tracks, 1 held Viking Therapeutics (VKTX) at the end of Q2 2026, their latest 13Fs. Against the quarter before, 1 added or bought in and 0 reduced or sold out. Between Jan 2, 2026 and Aug 1, 2026, Viking Therapeutics (VKTX) insiders filed 40 Form 4 transactions: 15 sales worth $17.8M in total and 1 open-market purchase worth $149,912.5. No Schedule 13D or 13G is on file for VKTX from the activists and large holders the site follows.
Every 13F filer's holdings of VKTX are not in yet — they come from SEC's quarterly 13F data sets. Meanwhile, the superinvestors the site tracks:
Superinvestors
| Manager | Quarter | Shares | Move | Value |
|---|---|---|---|---|
| Bridgewater · Bridgewater Associates, LP | Q2 2026 | 87,859 | added +23% | $3.4M |
A 13F is a quarterly snapshot filed up to 45 days after quarter end; 13D/13G are filed above 5%; a Form 4 within two business days of a trade. Insider holdings are the shares each person holds directly — trusts, family and other indirect holdings are reported on lines of their own and are not added in. Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Superinvestor names link to their full books under Investors; method notes in the manual.